Market Access Matters

Understanding Payer Perceptions with Megan O'Brien

In this episode, we hear from Megan O'Brien, Associate Director at Access Infinity, to explore why understanding payer perception is so difficult to capture in a str

Pricing Under Pressure: What MFN Really Means for Global Strategy

Most Favored Nation (MFN) pricing has taken over conversations at conferences, client meetings, and boardrooms alike, but what does it actually mean in practice? In this

Navigating Global Policy Shifts with Nikhil Taxak

In this episode we sit down with Nikhil Taxak, Head of Pricing and Market Access Data Analytics at Access Infinity, to explore the rapidly evolving market access landscap

Beyond the Headlines: Understanding MFN's True Impact on Market Access

In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy a

Revolutionary Strategies in Orphan Drug Development with Isabel Rubio

In this episode, we invite Access Infinity Partner, Isabel Rubio back to the podcast  to explore the unique challenges and innovative solutions reshaping market access an

Elevating launch excellence: The strategic value of early market access involvement with Lizzie Shanahan, Sanofi

In this insightful episode we speak with Lizzie Shanahan, Global Access AI Strategy Lead at Sanofi. With over six years' experience at Sanofi and a rich background i

Getting ready for the JCA: Why cross-functional collaboration matters with Silvy Mardiguian, BeiGene

In this episode, we speak with Silvy Mardiguian, Senior Director and Head of HEOR for Europe & New Markets at BeiGene.   Silvy has been co-leading BeiGene’s preparedness

The rise of multi-stakeholder capitalism in market access with Jie Shen, CSL

In this episode we chat with Jie Shen, who is Vice President Global Head Market Access at CSL.  Having started her career in pharma before the market access function exi

Authentic leadership in Market Access with Katrin Jack, Galderma

We're kicking off 2025 with a fantastic podcast episode featuring Katrin Jack, Global Access Strategy Head at Galderma and President of the Healthcare Businesswomen&

Market Access in emerging markets with Ezgi Erdogan, GSK

In this episode we speak with Ezgi Erdogan who is Oncology Market Access Director for Emerging Markets at GSK.  In this discussion, we cover the unpredictability of emer

Why Market Access requires unique thinking with UCB's Pauline Payen

In this episode, we sit down with Pauline Payen, Director and Global Payer Strategy Lead for UCB’s Early Portfolio. Pauline shares her pragmatic insights into navigating

The role of resilience in market access with Rupert Gale from GSK

In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale.  Rupert has been in pharma for over 27 years and is still going

Exploring value demonstration in market access with Korinna Karampampa, CSL Behring

Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development.  Korinna shares

Connecting the dots: Market access in the biotech industry with Ning Lu, Blueprint Medicines

In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines. Nin

What it takes to thrive as a strategic partner in market access with Marco Rauland, Merck KGaA

There’s no doubt that Market Access and Pricing leaders are fast becoming strategic partners in helping their wider organisations to understand the critical role of the f

Yvonne Hilsky, Moderna, on why it's important to understand the building blocks of market access.

In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it

Raising awareness on Disability with Shubham Jadhav

In this special episode which coincides with Disability Pride Month, we're joined by Senior Analyst Shubham Jadhav. Shubham has Becker Muscular Dystrophy (BMD) which

Exploring Canada's market access landscape with Sam Stankovic, Incyte Biosciences Canada

Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversat

Market access challenges and changes: Joao Carrasco talks data, AI and predicting uncertainties

In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Acc

Sanofi's Becky Germino on communicating value, AI and the role of HEOR in supporting access & pricing leaders

In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma